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Introduction {#osp452-sec-0005}
============

In 2014, there were more than 1.9 billion adults classified as overweight, of which 600 million were classified as obese (11% of men and 15% of women). These figures are double what they were in the 1980s, a clear indication that obesity is spreading widely across the globe. The obesity epidemic is now associated with more deaths globally than underweight [1](#osp452-bib-0001){ref-type="ref"}.

A widely used strategy to lose weight is caloric restriction (CR) [2](#osp452-bib-0002){ref-type="ref"}. A common CR method that became popular in the 1980s was very‐low‐calorie dieting (VLCD) [3](#osp452-bib-0003){ref-type="ref"}. VLCD is by definition prescribing fewer than 800 calories to be consumed daily [4](#osp452-bib-0004){ref-type="ref"}. Although VLCD has been shown to be an effective weight loss strategy in the short term [3](#osp452-bib-0003){ref-type="ref"}, it has also been argued that its risk of weight regain is greater due to its association with binge eating disorder [5](#osp452-bib-0005){ref-type="ref"}, behavioural fatigue [6](#osp452-bib-0006){ref-type="ref"} and loss of fat free mass [7](#osp452-bib-0007){ref-type="ref"}.

Intermittent CR regimens were designed to improve adherence [8](#osp452-bib-0008){ref-type="ref"}. An intermittent CR regimen that has recently emerged is alternate‐day‐fasting (ADF). With ADF, there is a fasting day, during which typically 25% of the dieter\'s estimated energy needs (typically \<800 calories/day) are consumed, followed by a normal feeding day when food and liquids are consumed *ad libitum* [9](#osp452-bib-0009){ref-type="ref"}. ADF has been associated with lower risk of weight regain, perhaps due to better compliance [10](#osp452-bib-0010){ref-type="ref"} and with relative preservation of fat‐free mass [7](#osp452-bib-0007){ref-type="ref"}.

Aside from the possible weight control benefits, at least in some animal studies, fasting or ADF appears to have multiple health‐promoting effects, notably related to aging, cancer, inflammation and neurodegeneration [11](#osp452-bib-0011){ref-type="ref"}. With respect to aging, one study has suggested that ADF can increase the life span of rodents by up to 80%. The possible mechanism of this effect is that fasting decreases glucose levels and insulin‐like growth factor (IGF‐1), which are aging promoters [12](#osp452-bib-0012){ref-type="ref"}. With respect to cancer, a study has suggested that ADF greatly reduces the incidence of lymphoma in mice [13](#osp452-bib-0013){ref-type="ref"}, and another study found that fasting one day per week may delay oncogenesis in p53‐missing mice [14](#osp452-bib-0014){ref-type="ref"}. In addition, a recent study concluded that by reducing glucose levels, insulin and ketone bodies, intermittent fasting may create a difficult environment for cancer cells to survive, thus improving the action of chemotherapeutic agents [15](#osp452-bib-0015){ref-type="ref"}.

In humans, a recent study has shown that intermittent fasting reduces oxidative stress and inflammation and it improves cellular glucose uptake and insulin sensitivity [11](#osp452-bib-0011){ref-type="ref"}. In addition, two studies have shown that fasting may improve neurologic function in the following ways: by increasing the levels of antioxidants, neurotropic factors and protein chaperones, and reducing the level of pro‐inflammatory markers [16](#osp452-bib-0016){ref-type="ref"}, and by upregulating the expression of synaptic plasticity‐related proteins, as well as anti‐apoptotic pathways [17](#osp452-bib-0017){ref-type="ref"}.

In terms of body composition, a study showed that intermittent fasting reduces body weight, fat mass, waist circumference and blood pressure [18](#osp452-bib-0018){ref-type="ref"}. The same authors stated that the metabolic effects of intermittent fasting include reductions in total cholesterol, LDL and triglycerides, as well as improvement of satiety through reductions in Leptin and Resistin, and increases in Adiponectin [18](#osp452-bib-0018){ref-type="ref"}.

A recent review comparing weight loss reported using daily CR and intermittent CR found that intermittent CR was as effective as daily CR in reducing body weight as well as in preserving fat‐free mass [7](#osp452-bib-0007){ref-type="ref"}. In the present review, we compared two types of severely energy‐restricted diets, achieved through either daily energy restriction or every‐other‐day energy restriction.

We systematically reviewed the efficacy of ADF diets compared to VLCD (the control) in terms of weight loss, and reduction of fat mass and fat‐free mass. Our objective was to explore the hypothesis that ADF could be an effective alternative to more restrictive dieting approaches, namely VLCD.

Methods {#osp452-sec-0006}
=======

Data sources {#osp452-sec-0007}
------------

Literature searches were conducted using PubMed, with the time frame of publication 1 January 2000 to 30 September 2015. An example of search commands is detailed as follows:

(Caloric restriction \[tiab\] OR VLED \[tiab\] OR LED \[tiab\] OR very low energy diet \[tiab\] OR low energy diet \[tiab\] OR LCD \[tiab\] OR 25% energy deficit weight loss diet \[tiab\] OR calorie restriction \[tiab\] OR Modifast \[tiab\] OR very‐low‐calorie diet \[tiab\] OR dietary restriction \[tiab\] OR daily energy restriction \[tiab\] OR VLCD \[tiab\] OR energy restriction \[tiab\] OR low calorie \[tiab\] OR very low calorie dietary intervention \[tiab\] OR continuous energy restriction \[tiab\] OR CER \[tiab\] OR continuous diet\[tiab\] OR alternate day fasting\[tiab\] OR ADF\[tiab\] OR every other day fast\[tiab\] OR ADMF\[tiab\] OR ad libitum every other day\[tiab\] OR ADCR diet\[tiab\] OR alternate day calorie restriction\[tiab\] OR modified alternate fasting\[tiab\] OR intermittent fasting\[tiab\] OR diet in every other day\[tiab\] ) AND \"weight loss\"\[Mesh\]

Study selection and criteria {#osp452-sec-0008}
----------------------------

The following exclusion criteria were applied: case reports, letters, comments, reviews or animal studies; languages other than English; and publication date other than from 1 January 2000 to 30 September 2015. The following inclusion criteria were applied: adults aged 18--70 years, with BMI ≥25 kg/m^2^, good general state of health (i.e. without a diagnosed condition), on only very‐low‐energy diets (\<800 calories/d) for VLCD studies and interventions lasting between 3 and 12 weeks.

Data extraction {#osp452-sec-0009}
---------------

Studies were selected for data extraction if they met the above inclusion and exclusion criteria and reported at least weight loss data. We only included study arms where diet only was used; we excluded any arms that used physical activity or drugs to ensure better comparability between study interventions. Sample size and intervention length were recorded. Characteristics of the initial study sample (e.g. age, sex and weight), baseline body weight, fat mass, fat‐free mass and waist circumference were captured when available. Conversion of units to keep data comparable was implemented when necessary. Two reviewers independently reviewed the studies, extracted data and then resolved disparities by agreement (Supplementary Table S1, available as Supplementary data at *OSP* online).

Quality assessment {#osp452-sec-0010}
------------------

Two reviewers used the Downs and Black quality checklist to assess the risk of study bias (ROB) for each included study [19](#osp452-bib-0019){ref-type="ref"}: (i) low ROB: when a study fulfilled all the following criteria: stated the objective, described the main outcomes, described the characteristics of the enrolled subjects, clearly described the interventions, described the main findings, randomized the subjects to the intervention groups, concealed the intervention assignments until recruitment was complete and partially or fully described the distribution of potential confounders in each treatment group; (ii) moderate ROB: if a study did not fulfil one of the above criteria, or if such could not be verified and (iii) high ROB: if a study did not fulfil more than one of the above criteria.

Statistics and meta‐analysis {#osp452-sec-0011}
----------------------------

All statistical analysis were pre‐specified. The dietary interventions were grouped into two sets: ADF and VLCD. Study‐level data were summarized using descriptive statistics. If not reported, the standard error of means were computed using the following formula: SE = SD/ √n. STATA 14 was used both for the meta‐analysis and the meta‐regression. The random‐effects meta‐analysis approach was performed to estimate the overall difference in each intervention. Meta‐regression models were used to adjust for BMI and length of intervention. The residual maximum‐likelihood method was used to estimate the additive (between‐study) component of variance Tau^2^. Heterogeneity was tested using I^2^ test. The *p*‐values calculated by Monte Carlo permutation test were used to address multiple testing. A statistically significant difference was defined by a *p*‐value less than 0.05.

Results {#osp452-sec-0012}
=======

Data retrieval {#osp452-sec-0013}
--------------

A flow chart showing the systematic review process is provided in Figure [1](#osp452-fig-0001){ref-type="fig"}. The initial search resulted in 2,357 publications. After applying the exclusion criteria, 627 remained. The full text of these studies was then retrieved, and after screening for inclusion criteria, data were extracted from 28 studies, 6 ADF and 22 VLCD studies. Four articles contributed to more than one arm of the analysis. Only the 10 studies that reported the change with standard errors for all three outcomes of interest (i.e. weight loss, fat mass and fat‐free mass were included in the meta‐analysis) (Figure [1](#osp452-fig-0001){ref-type="fig"}).

![Flow chart of the systematic review process.](OSP4-2-293-g001){#osp452-fig-0001}

Characteristics of study participants {#osp452-sec-0014}
-------------------------------------

A total of 1,193 study participants were included in the analyses, 132 who underwent ADF and 1,060 who underwent VLCD. For ADF studies reporting this information, mean age of participants was 42.33 years, 92.42% were female, mean BMI was 33.17 kg/m^2^, mean baseline body weight was 90.28 kg, mean fat mass was 38.06 kg, mean fat‐free mass was 48.32 kg and mean waist circumference was 97.70 cm. For the VLCD studies, mean age of participants was 40.04 years, 67.76% were female, mean BMI was 31.15 kg/m^2^, mean baseline body weight was 83.55 kg, mean fat mass was 31.34 kg, mean fat‐free mass was 44.52 kg and mean waist circumference was 100.56 cm (Table [1A](#osp452-tbl-0001){ref-type="table-wrap"}).

###### 

Patient characteristics

  Patient characteristics    ADF (132)   VLCD (1,060)
  -------------------------- ----------- --------------
  Age (years)                42.33       40.04
  Females (%)                92.42       67.76
  BMI (kg/m^2^)              33.17       31.15
  Body weight (kg)           90.28       83.55
  Fat mass (kg)              38.06       31.34
  Fat‐free mass (kg)         48.32       44.52
  Waist circumference (cm)   97.70       100.56

ADF, alternate‐day fasting; BMI, body mass index; VLCD, very‐low‐calorie‐diets.

Characteristics of included studies {#osp452-sec-0015}
-----------------------------------

For the included ADF studies, one was published between 2000 and 2010, and five between 2011 and 2015. Two studies had intervention durations of 3--8 weeks, and four 9--12 weeks. Four studies were conducted in North America and two in Asia. Of the included VLCD studies, 14 were published between 2000 and 2010, and eight between 2011 and 2015. Eighteen had intervention durations of 3--8 weeks, and four 9--12 weeks. Nineteen were conducted in Europe and three in Australia (Table [1B](#osp452-tbl-0002){ref-type="table-wrap"}).

###### 

Study characteristics

  Study characteristics   Number of studies (ADF)   Number of participants   Number of studies (VLCD)   Number of participants
  ----------------------- ------------------------- ------------------------ -------------------------- ------------------------
  *Publication year*                                                                                    
  2000--2010              1                         16                       14                         883
  2011--2015              5                         116                      8                          177
  *Intervention length*                                                                                 
  3--8 weeks              2                         41                       18                         917
  9--12 weeks             4                         91                       4                          143
  *Study location*                                                                                      
  North America           4                         91                                                  
  Europe                                                                     19                         1,000
  Asia                    2                         41                                                  
  Other                                                                      3                          60

ADF, alternate‐day fasting; VLCD, very‐low‐calorie‐diets.

Of the 28 studies included in the systematic review (Supplementary Table S2, available as Supporting Information at *OSP* online), after applying quality assessment based on Downs and Black criteria [19](#osp452-bib-0019){ref-type="ref"}, 20 had high ROB, 7 had moderate ROB and 1 had low ROB. Of the 10 studies used in the meta‐analysis, 5 had high ROB and 5 had moderate ROB.

Missing data {#osp452-sec-0016}
------------

Gender reporting was missing in three studies, age reporting in six and BMI reporting in one study. Baseline body weight was missing in 3 studies, fat mass in 11, fat‐free mass in 18 and waist circumference in 12 studies.

Characteristics of the studies included in the meta‐analysis {#osp452-sec-0017}
------------------------------------------------------------

Table [2A](#osp452-tbl-0003){ref-type="table-wrap"} details the 10 studies included in the meta‐analysis: 4 ADF and 6 VLCD. Mean age of the 662 participants included in the meta‐analysis was 44.69 ± 1.9 years, mean BMI was 31.31 kg/m^2^ and 78.06% were females. ADF studies were all grant funded, while all of the VLCD studies were industry funded.

###### 

Studies included in the meta‐analysis

  Name                                                                                             Sample size (*n*)   Females(%)   Age [\*](#osp452-note-0003){ref-type="fn"} (years)   Baseline BMI[\*](#osp452-note-0003){ref-type="fn"}   Length (weeks)   Change in body weight[\*](#osp452-note-0003){ref-type="fn"} (kg)   Change in fat mass[\*](#osp452-note-0003){ref-type="fn"} (kg)   Change in fat‐free mass[\*](#osp452-note-0003){ref-type="fn"} (kg)
  ------------------------------------------------------------------------------------------------ ------------------- ------------ ---------------------------------------------------- ---------------------------------------------------- ---------------- ------------------------------------------------------------------ --------------------------------------------------------------- --------------------------------------------------------------------
  *ADF*                                                                                                                                                                                                                                                                                                                                                                                           
  Varady, 2013 [20](#osp452-bib-0020){ref-type="ref"}                                              15                  66           47 ± 3.0                                             26 ± 1.0                                             12               5.20 ± 0.9                                                         3.60 ± 0.7                                                      1.60 ± 0.5
  Bhutani, 2013 [21](#osp452-bib-0021){ref-type="ref"}                                             25                  96           40 ± 2.0                                             35 ± 1.0                                             12               3.00 ± 1.0                                                         2.00 ± 1.0                                                      1.00 ± 1.0
  Klemple, 2013 (HF) [9](#osp452-bib-0009){ref-type="ref"}                                         17                  100          42 ± 3.0                                             35 ± 0.7                                             8                4.30 ± 1.0                                                         5.40 ± 1.5                                                      1.10 ± 1.3
  Klemple, 2013 (LF) [9](#osp452-bib-0009){ref-type="ref"}                                         18                  100          43 ± 2.0                                             36 ± 0.7                                             8                3.70 ± 0.7                                                         4.20 ± 0.6                                                      0.50 ± 0.7
  Varady, 2009 [10](#osp452-bib-0010){ref-type="ref"}                                              16                  75           46 ± 2.0                                             34 ± 1.0                                             8                5.60 ± 1.0                                                         5.40 ± 0.8                                                      0.10 ± 0.1
  *VLCD*                                                                                                                                                                                                                                                                                                                                                                                          
  Munro, 2013 (placebo) [22](#osp452-bib-0022){ref-type="ref"}                                     19                  79           47 ± 2.0                                             34 ± 0.8                                             4                5.79 ± 0.4                                                         4.19 ± 0.4                                                      1.33 ± 0.4
  Munro, 2013 (fish oil)[22](#osp452-bib-0022){ref-type="ref"}                                     20                  75           45 ± 2.0                                             31 ± 0.6                                             4                6.12 ± 0.3                                                         4.36 ± 0.3                                                      1.68 ± 0.3
  Westerterp‐P, 2005[†](#osp452-note-0004){ref-type="fn"} [23](#osp452-bib-0023){ref-type="ref"}   76                  70                                                                28 ± 0.3                                             4                5.90 ± 0.2                                                         5.00 ± 0.2                                                      2.50 ± 0.5
  Lejeune, 2005 [24](#osp452-bib-0024){ref-type="ref"}                                             113                              45 ± 1.0                                             29 ± 0.2                                             4                6.30 ± 0.3                                                         4.00 ± 0.3                                                      2.30 ± 0.2
  Westerterp‐P, 2004 [25](#osp452-bib-0025){ref-type="ref"}                                        148                              44 ± 0.8                                             30 ± 0.2                                             4                6.40 ± 0.1                                                         3.90 ± 0.3                                                      2.50 ± 0.2
  Kovacs, 2004 [26](#osp452-bib-0026){ref-type="ref"}                                              104                 75                                                                30 ± 0.3                                             4                6.40 ± 0.3                                                         4.00 ± 0.3                                                      2.40 ± 0.3
  Lejeune, 2003 [27](#osp452-bib-0027){ref-type="ref"}                                             91                                                                                    29 ± 0.3                                             4                6.60 ± 0.2                                                         4.10 ± 0.2                                                      2.50 ± 0.2

Mean [+]{.ul} SEM.

Numbers were computed from one figure of the article.

ADF, alternate‐day fasting; BMI, body mass index; HF, high fat group; LF, low fat group; VLCD, very‐low‐calorie‐diets.

Meta‐analysis results {#osp452-sec-0018}
---------------------

Unadjusted values show that compared to the VLCD studies, ADF participants had a smaller loss in body weight (−1.99 kg, 95% confidence interval \[CI\]: −2.94, −1.04) and a smaller loss in fat‐free mass (−1.60 kg, 95% CI: −2.40, −0.80), while no significant change was observed between diet interventions in fat mass (−0.16 kg, 95% CI: −1.19, 0.87) (Table [2B](#osp452-tbl-0004){ref-type="table-wrap"}).

###### 

Meta‐regression results

  Variables              Unadjusted (95% CI)    *P*‐value   Adjusted (95% CI)      *P*‐value
  ---------------------- ---------------------- ----------- ---------------------- -----------
  *Body weight (kg)*                                                               
  ADF                    −1.99 (−2.94, −1.04)   \<0.01      −0.88 (−4.32, 2.56)    0.57
  BMI                                                       −0.08 (−0.26, 0.09)    0.28
  Length                                                    −0.14 (−0.68, 0.40)    0.56
  *Fat mass (kg)*                                                                  
  ADF                    −0.16 (−1.19, 0.87)    0.73        3.31 (0.05, 6.56)      0.05
  BMI                                                       −0.10 (−0.27, 0.06)    0.19
  Length                                                    −0.57 (−1.08, −0.05)   0.03
  *Fat‐free mass (kg)*                                                             
  ADF                    −1.60 (−2.40, −0.80)   \<0.01      −1.69 (−3.62, 0.23)    0.07
  BMI                                                       −0.18 (−0.33, −0.03)   0.02
  Length                                                    0.06 (−0.28, 0.41)     0.68

ADF, alternate‐day fasting; BMI, body mass index; CI, confidence interval; VLCD, very‐low‐calorie‐diets.

After adjustment for BMI and duration of the dietary intervention, there was no significant difference between interventions in body weight (−0.88 kg, 95% CI: −4.32, 2.56) or fat‐free mass (−1.69 kg, 95% CI: −3.62, 0.23) (Table [2B](#osp452-tbl-0004){ref-type="table-wrap"}). There was a significant difference between interventions in that the adjusted loss of fat mass on the ADF regimens was 3.31 kg greater than on the VLCD regimens (95% CI: 0.05, 6.56).

Regarding change in body weight, Figure [2](#osp452-fig-0002){ref-type="fig"} shows that, among ADF studies, the smallest reduction was 3.00 kg (95% CI: 1.04, 4.96) and the greatest reduction was 5.60 kg (95% CI: 3.64, 7.56). The pooled change was 4.30 kg (95% CI: 3.41, 5.20). Among the VLCD studies, the smallest reduction in body weight was 5.79 kg (95% CI: 4.92, 6.65) and greatest reduction was 6.40 kg (95% CI: 5.81, 6.98). The pooled change was 6.28 kg (95% CI: 6.08, 6.49).

![ADF versus VLCD: body weight difference pooled results.](OSP4-2-293-g002){#osp452-fig-0002}

With regard to change in fat mass, Figure [3](#osp452-fig-0003){ref-type="fig"} shows that, among ADF studies, the smallest reduction was 2.00 kg (95% CI: 0.04, 3.96) and the greatest was 5.40 kg (95% CI: 3.83, 6.97). The pooled change was 4.06 kg (95% CI: 2.99, 5.13). For the VLCD studies, the smallest reduction in fat mass was 3.90 kg (95% CI: 3.31, 4.49) and greatest was 5.00 kg (95% CI: 4.41, 5.59). The pooled change was 4.22 kg (95% CI: 3.95, 4.50).

![ADF versus VLCD: fat mass difference pooled results.](OSP4-2-293-g003){#osp452-fig-0003}

For change in fat‐free mass, Figure [4](#osp452-fig-0004){ref-type="fig"} shows that, among ADF studies, the smallest reduction was 0.10 kg (95% CI: −0.1, 0.30) and the greatest 1.60 kg (95% CI: 0.62, 2.58). The pooled change was 0.72 kg (95% CI: −0.07, 1.51). Among the VLCD studies, the smallest reduction was 1.33 kg (95% CI: 0.59, 2.07) and the greatest 2.50 kg (95% CI: 2.10, 2.89). The pooled change was 2.24 kg (95% CI: 1.95, 2.52).

![ADF versus VLCD: fat‐free mass difference pooled results.](OSP4-2-293-g004){#osp452-fig-0004}

Discussion {#osp452-sec-0019}
==========

This is the first paper to perform a systematic review together with a meta‐analysis comparing ADF and VLCD regimens in terms of weight, fat mass and fat‐free mass reduction.

Our meta‐analysis shows that both dietary interventions are efficacious, resulting in substantial body weight loss. Although the magnitude of weight loss by VLCD is somewhat greater, ADF results in greater relative reduction of fat mass and lesser reduction of fat‐free mass.

While magnitude of initial weight loss is greater using VLCD, studies have shown, however, that VLCD may increase the risk of headache, fatigue, dizziness, hair loss, constipation and dehydration. As a result, it requires regular medical supervision [28](#osp452-bib-0028){ref-type="ref"}, [29](#osp452-bib-0029){ref-type="ref"}, [30](#osp452-bib-0030){ref-type="ref"}, [31](#osp452-bib-0031){ref-type="ref"}. Also, VLCD has been associated with an increased risk of developing gallstones; one study showed that after 8 weeks of VLCD, 25% of patients developed gallstones and 6% required cholecystectomy [32](#osp452-bib-0032){ref-type="ref"}. VLCD may also be associated with development of binge eating disorder. Following a VLCD regimen one study showed that the disorder developed among 62% of subjects, but decreased among 39% [33](#osp452-bib-0033){ref-type="ref"}. However, Wadden *et al.* (1994) found no difference in binge‐eating occurrence or in weight loss among binge eaters versus non‐binge eaters who were both following a VLCD regimen. Their hypothesis was that binge eaters might find VLCD easier to follow than conventional calorie‐restrictive diets [34](#osp452-bib-0034){ref-type="ref"}.

In their meta‐analysis, Tsai and Wadden (2006) concluded that VLCD may be a viable option to lose weight in the short term; however, they found that patients failed to maintain 15 to 25% of VLCD‐associated initial weight loss, due to difficult compliance, adaptive hormonal changes and our toxic food environment [3](#osp452-bib-0003){ref-type="ref"}.

We found that ADF may be as effective as even the very restrictive VLCD with respect to fat‐mass reduction, and provides relative preservation of fat‐free mass. Two recent reviews have evaluated the effects of intermittent diets versus daily CR on weight loss, fat mass and fat‐free mass [7](#osp452-bib-0007){ref-type="ref"}, [35](#osp452-bib-0035){ref-type="ref"}. One (non‐systematic) reported fat‐free mass preservation by the intermittent diets [7](#osp452-bib-0007){ref-type="ref"}, while the other one (systematic) reported no difference between the diets [35](#osp452-bib-0035){ref-type="ref"}.

In our review, efficacy of ADF for weight‐ and fat‐mass reduction was an expected finding, and it is most likely explained by the substantial overall decrease in energy intake that adherence to alternate‐day energy restriction will provide. It is noteworthy, however, that as prescribed, VLCD would provide somewhat greater levels of energy restriction than ADF, as it generally provides a \>50% reduction in estimated energy needs [4](#osp452-bib-0004){ref-type="ref"}. This implies logically that in order for mean weight and fat loss on ADF regimens to be as good as that achieved on VLCD regimens, average compliance with ADF must have been superior to compliance with VLCD.

On the other hand, preservation of fat‐free mass, at the cost of fat mass during weight reduction [18](#osp452-bib-0018){ref-type="ref"} is unexpected with the level of energy restriction that ADF prescribes. To our knowledge, this is the first review to report this finding. The mechanism for this effect, if confirmed by other studies, is unclear, although it is possible that either the fasting period is brief enough that there is less loss of lean tissue in the first place, or that the days where full energy needs are met allow for recovery of fat‐free mass by rebuilding lean tissue lost on the fasting days.

Several studies have reported that ADF did not appear to cause a hyperphagic response on the feeding day [9](#osp452-bib-0009){ref-type="ref"}, [20](#osp452-bib-0020){ref-type="ref"}, [21](#osp452-bib-0021){ref-type="ref"}, which may have facilitated the subjects\' ability to maintain a substantial level of mean energy restriction. In line with this, Klempel *et al.* (2010) conducted a modified ADF study and found that, on feeding days, subjects only consumed 95% of their calculated energy intake [36](#osp452-bib-0036){ref-type="ref"}. ADF has also been found to decrease hunger and increase satiety and dieting satisfaction in 8 to 12‐week studies, all of which may enhance the adherence to the diet [7](#osp452-bib-0007){ref-type="ref"}, [9](#osp452-bib-0009){ref-type="ref"}. The possible mediators of these appetite effects include reductions in Leptin and Resistin, and increases in Adiponectin [18](#osp452-bib-0018){ref-type="ref"}. While a counter‐intuitive approach to weight control, it has been argued that ADF regimens may achieve relatively high levels of dietary adherence because they require energy restriction only every other day [10](#osp452-bib-0010){ref-type="ref"} and do not require a change in the types of food consumed, but rather a change in the pattern of consumption [9](#osp452-bib-0009){ref-type="ref"}. Varady *et al.* (2009) reported ADF efficacy for weight reduction even during self‐implementation periods [10](#osp452-bib-0010){ref-type="ref"}. For all the reasons presented earlier, we consider ADF a viable alternative approach to weight control, as also suggested by others [37](#osp452-bib-0037){ref-type="ref"}.

As with any diet for weight loss, ADF reduction in body weight was related to the level of adherence to this dietary intervention [18](#osp452-bib-0018){ref-type="ref"}, [38](#osp452-bib-0038){ref-type="ref"}, [39](#osp452-bib-0039){ref-type="ref"}. Its efficacy in at least one of the reviewed studies was maximized when combined with exercise at least three times per week [21](#osp452-bib-0021){ref-type="ref"}. However, a very recent study by Barnoski *et al.* (2015) -- who examined whether ADF improves eating behaviours in a way that promotes successful weight loss and weight loss maintenance -- observed a reduction in body weight even without a change in physical activity [40](#osp452-bib-0040){ref-type="ref"}. The same study observed no changes in appetite ratings (hunger, satisfaction and fullness), dietary restraint, emotional eating, uncontrolled eating or self‐efficacy in the ADF or the calorie restriction groups as compared to the control. The authors concluded that the role of beneficial eating behaviours in body weight reduction through ADF or CR remains unclear [40](#osp452-bib-0040){ref-type="ref"}, hence warranting further research.

In line with other recent studies, the first finding of our review is that ADF appears to be an effective strategy for initial weight loss (at least the first eight weeks) in overweight and subjects with obesity. But most importantly, our review suggests that ADF may be superior to daily CR in terms of type of weight lost (fat vs. non‐fat), and adherence.

Health risks may also be affected favourably by ADF. Waist circumference, a marker of visceral obesity which is associated with coronary heart disease and diabetes [41](#osp452-bib-0041){ref-type="ref"}, [42](#osp452-bib-0042){ref-type="ref"}, was reduced by 4--10% from baseline in the studies reviewed, and correlated with overall weight reduction [7](#osp452-bib-0007){ref-type="ref"}, [10](#osp452-bib-0010){ref-type="ref"}, [43](#osp452-bib-0043){ref-type="ref"}. Adherence to this regimen was also associated with a decrease in triglycerides, total cholesterol and LDL. These effects were also correlated with the reduction in body weight and visceral fat. The possible mechanism by which ADF alters lipids is via an increase in oxidation of free fatty acids during periods of weight loss, while free fatty acid synthesis is reduced [44](#osp452-bib-0044){ref-type="ref"}. This leads to a reduction in very low density lipoprotein (VLDL) synthesis by the liver and thus reduced circulating levels of LDL [45](#osp452-bib-0045){ref-type="ref"}. Thus, adherence to an ADF diet may be cardio protective.

This review was limited by the small number of ADF studies published to date, necessitating the inclusion of non‐randomized clinical trials. Furthermore, of the studies that were included in this review, there was an over representation of women on the ADF regimens (92%). Glucose response in women is adversely affected following a fast [46](#osp452-bib-0046){ref-type="ref"}; therefore, it is possible that gender differences in physiologic response to the ADF regimen may have affected our analysis. Animal studies have suggested that gender plays an important role in the evolutionary adaptation to fasting. One study found that only female mice demonstrated increases in arousal and reduced Gherlin, suggesting that women may stand to achieve greater benefit from ADF [47](#osp452-bib-0047){ref-type="ref"}. While these differences, on a physiologic level, are important in determining which diet may be most appropriate for a given patient, it is important to note that no gender differences in weight loss have yet been shown in human studies [48](#osp452-bib-0048){ref-type="ref"}. Better responses to the ADF have, however, been shown in older individuals and Caucasians, but we were unable to assess this from the papers included in this review [48](#osp452-bib-0048){ref-type="ref"}.

Conclusion {#osp452-sec-0020}
==========

Among individuals with obesity, ADF is an efficacious dietary method, and may be superior to VLCD for some patients because of ease of compliance, greater fat‐mass loss and relative preservation of fat‐free mass. However, further studies comparing ADF to VLCD (ideally head‐to‐head randomized clinical trials) that also control for patient characteristics, are needed to confirm the efficaciousness of these two approaches for weight loss, and to determine if ADF is better suited to certain populations. This information is of interest to health care providers and dietitians, as well as individuals with obesity seeking effective and potentially easier to follow methods to lose weight.
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